Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016

Harnessing Precision Genome Editing
Applications for Advanced Biomedical
Research & Therapeutic Development
Tel: +44 (0)20 3141 8700 | Email: info@hansonwade.com CRISPR Precision Gene Editing
Researched & Developed By:www.crispr-europe.com
24th-26th October 2016 | Berlin, Germany
Lead Partner Additional Partners
Book now and save up to 4400
Bill Lundberg
CRISPR Therapeutics
John Feder
Bristol-Myers Squibb
Daniel Anderson
MIT
John van der Oost
Wageningen UR
Danilo Maddalo
Novartis Institutes for BioMedical Research
Lennart Randau
Max-Planck-Institute

1 1
3 3
2 2
4 4
5 5
Advance your understanding of CRISPR and
Cas9 mechanisms to optimise downstream
applications of precision gene-editing
technology
Explore how Max-Planck are taking
learnings from CRISPR/Cas structures and
mechanisms in bacteria to identify target
specificity
Develop optimised workflows to
effectively integrate CRISPR technology
into basic and biomedical research
Learn how Pfizer are integrating
CRISPR technology for optimised target
validation through CRISPR libraries
Integrate CRISPR technology in disease
modelling and genome-wide screening to
advance target identification and validation
Discover how Takeda Cambridge are
developing customized designed IPS cells
for in vitro disease modelling
Top 5 Key Takeaways Top 5 Ideas to Implement
Understand the regulatory environment
for utilising CRISPR technology in crop
breeding and take those learnings into
your industry
Learn from Karolinska Institutet &
Novartis on how to harness CRISPR-
based genome-wide screening for
optimised target identification
Harness precision gene engineering to
develop cell-based therapies in oncology
Discover how Cellectis are clinically
utilising TALENs to develop CAR-T
therapies
Benefits of Attending
Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com
www.crispr-europe.com
CRISPR & Precision Gene Editing Congress Europe
Berlin, Germany | 24th
-26th
October 2016
CRISPR Precision Gene Editing
The Only Industry Congress Solely Dedicated to Optimising the
Applications of CRISPR Precision Genome Editing in Europe
Develop your CRISPR workflows to power novel applications in target
identification, disease modelling and therapeutic development
The CRISPR & Precision Genome Editing Congress
Europe 2016 will continue to enhance and improve
the very latest applications of CRISPR technology
to pioneer basic research, biomedical research
and therapeutic applications of precise genome
engineering.
With customisation and optimisation of CRISPR design
paramount, join leading biopharma and academic
figureheads as they reveal advanced methodology,
strategies and clinical timelines to fulfil the
revolutionary promise of precision genome editing.
With beneficial applications of CRISPR increasing and
alternative systems rapidly being developed, safeguard
against future technical bottlenecks faced by early
adopters and new users alike by learning how to
optimise CRISPR workflows to enhance the integration
of precision gene editing within your research.
Discover how the industry is advancing the robustness
of current applications of CRISPR including: disease
modelling, target identification and validation,
genome-wide screening and development of CRISPR
therapeutics. Furthermore, as it establishes itself as
the leading editing tool, discover future applications on
the horizon.
In this truly innovative field, become part of the CRISPR
Europe Congress in 2016 and join those dedicated to
pioneering CRISPR/Cas9 to enhance applications in
basic research to R&D productivity and revolutionise
therapeutic development.

-26th
October 2016
Expert Speaker Faculty
Donald Apanovitch
Director, Functional
Genomics & Biolomics
Pfizer
Daniel Anderson
Sam Goldblith Associate
Professor
MIT
Bill Lundberg
Chief Scientific Officer
CRISPR Therapeutics
Ross Kettleborough
European Field
Applications Specialist
Twist Bioscience
Danilo Maddalo
Lab Head, Oncology
Pharmacology
Novartis Institutes for
BioMedical Research
Lennart Randau
Research Group Leader,
Terrestrial Microbiology
John Feder
Associate Director,
Genome Biology
John van der Oost
Professor, WU
Agrotechnology & Food
Sciences
Wageningen UR
Jonathan Chesnut
Senior Director, Synthetic
Biology R&D
Thermo Fisher Scientific
Evren Alici
Assistant Professor &
Research Group Leader
Karolinska Institutet
Roderick Beijersbergen
Group Leader, Division of
Molecular Carcinogenesis & NKI
Robotics & Screening Center
The Netherlands
Cancer Institute
Steve Sheardown
Transgenic Group Head
Takeda Cambridge
Laurent Poirot
Head of Early Discovery
Cellectis
Emma Shanks
Head of Screening
The Beatson Institute
Jennifer Berman
Staff Scientist, Applications,
Digital Biology Center
Bio-Rad Laboratories
Kosuke Yusa
Group Leader
Wellcome Trust
Sanger Institute
Alexander Espinosa
Assistant Professor
Niels Geijsen
Founder &
Scientific Advisor
NTrans
Petra Jorasch
Vice Secretary General
German Plant
Breeders’ Association
Beat Späth
Director Agricultural
Biotechnology
EuropaBio
Maria Celeste M. Ramirez
Director of
Product Marketing
Twist Bioscience
Leigh Brody
Director Genomic
Services
Desktop Genetics
Daniela Hüber
Gene Modulation Specialist,
Dharmacon
GE Healthcare
Speakers all gave
excellent presentations - perfect
balance of both academic and industry
viewpoints on leveraging CRISPR
technology. I enjoyed the format and
structured networking sessions were
well thought out. I also appreciated the
opportunity to connect with new experts
in this emerging field
Past Attendee,
Warp Drive Bio

Pre-Conference Workshops, Monday 24th October 2016
Workshop A
Workshop B
I really enjoyed
all the talks and the
variety in them, from pure
academic to industrial
application. I thought the
meeting was excellent
and well-worth it
Past Attendee,
Broad Institute
I was able to get
something out of
each presentation. It
was a total success
in my opinion
Past Attendee,
GlaxoSmithKline
-26th
October 2016
One key application of CRISPR precision gene editing is in the discovery and
functional understanding of genomics through high-throughput screening.
In this interactive workshop, you will capitalise lessons learned in order to:
• Optimise the implementation of CRISPR gene editing for target
identification and validation
• Discuss technical strategies to improve CRISPR applications both in vitro
and in vivo utilisation
• Harness protocols and strategies for large scale genome screens to
develop CRISPR libraries
CRISPR/Cas9-mediated genome editing has become a rapidly adopted
application in developing in vitro and in vivo preclinical models to better
understand the complexity of human disease.
In this interactive workshop, you will discover solutions and answers to
help you:
• Discover the impact of genome editing tools in preclinical investigation
in industry
• Overcome the current limitations of using CRISPR for disease modelling
• Learn about and discuss case studies to standardise protocols to utilise
CRISPR for in vitro and in vivo models
• Discover what information can we get from in vivo models
Enhancing CRISPR Technology for Target
Identification and Developing Genome-Wide CRISPR
Libraries within Oncology
Date: Monday 24th October 2016 Time: 9.00-12.00
Developing More Physiologically-Relevant Disease
Models With CRISPR for Improved Preclinical
Predictability
Date: Monday 24th October 2016 Time: 13.00-16.00
Danilo Maddalo
Lab Head, Oncology Pharmacology
Novartis Institutes for BioMedical
Research
Donald Apanovitch
Genomics & Biolomics
Pfizer
About Your Workshop Leader:
At Memorial Sloan Kettering Cancer Center, Dr
Maddalo established a model of chromosomal
rearrangements using the CRISPR/Cas9
technology. Dr Maddalo, now at Novartis
Institutes for Biomedical Research in Basel,
focuses on mouse modelling of disease for drug
discovery and target identification.
Very enjoyable and
informative meeting.
The workshops at
the beginning were
something new to me and
I found them a very useful
means of idea sharing
and networking
Past Attendee,
Boehringer Ingelheim
About Your Workshop Leader:
Donald manages the Functional Genomics
group in the Biolomics Department at Pfizer
Research. The group is responsible for
supporting the validation and/ or identification
of new therapeutic targets across multiple
therapeutic research areas using multiple
high content imaging platforms and RNAi
technologies.

Conference Day One, Tuesday 25th
October 2016
8.00 Registration & Breakfast
9.00 Chairman’s Opening Remarks
Scalpel Precision: Empowering CRISPR to be Even More Precise
9.10 A CRISPR Screen Identifies Genetic Vulnerabilities in Acute Myeloid Leukaemia
• Development and improvement of the CRISPR screening methodology for optimised
CRISPR workflows
• Applications of CRISPR gene editing for screening in oncology research
• Developing screening and libraries to identify genetic vulnerabilities in cancer cells
Ross Kettleborough,
European Field Applications
Specialist, TWIST
Bioscience
Kosuke Yusa, Group
Leader, Wellcome Trust
Sanger Institute
9.40 Understanding the Mechanistic Actions of Cpf1 to Optimise Efficiency of
CRISPR Precision Genome Editing
• Addressing Cpf1 mechanisms and how it is currently being applied
• Comparing and contrasting the mechanisms of Cpf1 to Cas9
• What is the current efficiency readout for Cpf1 compared to Cas9?
John van der Oost,
Professor, WU
Agrotechnology
& Food Sciences,
Wageningen UR
10.10 Modulating the Architecture of Minimal Type I CRISPR-Cas
Interference Complexes
• Reviewing the landscape of highly divergent CRISPR-Cas systems
in prokaryotes
• Highlighting important structural and functional differences, which can impact
target specificity
• Discussing the structural and targeting mechanisms, and the assembly of Cas protein
interference complexes termed Cascade
Lennart Randau,
Research Group Leader,
Terrestrial Microbiology,
10.40 Speed Networking & Morning Refreshments
Improving Customised Design of CRISPR Workflows & Effective Data Analysis
11.40 Ultra-Sensitive Quantification of Genome Editing Events by Droplet
Digital PCR
• Development and optimisation of genome editing methods for a sensitive, rapid-readout
tool for edit validation and off-target detection
• Droplet Digital PCR (ddPCR) enables sensitive (<0.1%), precise absolute quantification of
NHEJ and HDR alleles in a rapid, high-throughput format
Jennifer Berman,
Staff Scientist, Applications,
Digital Biology Center,
Bio-Rad Laboratories
12.10 Transitioning From siRNA Screens to CRISPR Screens: Experiences From
• Utilising high throughput functional genomics approaches with high content phenotypic
image analysis for target identification and validation across multiple cancer types using
both immortal and primary cell cultures derived from patient tumours
• Transitioning from siRNA-based screens using both pooled and deconvolved approaches
• Exploring the value of adding CRISPR to our workflow as a screening tool by conducting i)
genome-wide pooled sgRNA screens and ii) arrayed sgRNA phenotypic screens
• Comparative sgRNA and siRNA array evaluations using scalable cytotoxic, cytostatic and
cell migration platforms
• Evaluations using our PhenoTox panel, containing targets generating apoptotic, autophagic,
senescent, oxidative stress and ER stress phenotypes
Emma Shanks, Head of
Screening,
12.40 CRISPR-Based Genome Editing Tools: New Applications
& Improved Workflows
• Streamline and high throughput CRISPR tool production
• Discussing improvements in gene knock-out and editing efficiency
• Evaluating new and efficient platforms for CRISPR-based functional
genomics screening
Jonathan Chesnut,
Senior Director, Synthetic
Biology R&D,
-26th
October 2016

13.10 Networking Lunch
Advancing Disease Modelling & Large Scale Genome-Wide Screening
14.10 Genome Editing Meets Mouse Modelling for Better Preclinical Tools
• Highlighting the limitations of traditional mouse models
• Harnessing CRISPR for the precise development of physiologically relevant preclinical in
vivo models
• Examples how genome editing as a tool has been utilised to generate better preclinical
models
Danilo Maddalo,
Lab Head, Oncology
Pharmacology,
Novartis Institutes for
BioMedical Research
14.40 The Possibilities, Challenges & Success of CRISPR-Based Screening
for Target Identification
• Development and optimisation of screening models using CRISPR technology
• Selection of the best screening strategy
• Selection and follow-up of screening hits
Roderick Beijersbergen,
Group Leader, Division of
Molecular Carcinogenesis &
NKI Robotics &
Screening Center,
The Netherlands Cancer
Institute
15.10 Harnessing Fluorescent Properties of Small-Molecules for
CRISPR/Cas9 Screens
• Developing CRISPR screening protocols for target identification in oncology
• To harness the fluorescent properties of many anti-cancer drugs to identify unknown
drug targets and to understand mechanisms of drug resistance
Alexander Espinosa,
Assistant Professor,
15.40 Afternoon Refreshments & Poster Competition Hosted by Twist Bioscience
With an agenda packed with case studies and data-driven presentations, the CRISPR Europe poster session will allow you
deeper access into the most innovative research. Meet the scientists conducting exciting research and pick their brains to
gain insights into the emerging CRISPR gene editing applications. Apply their learnings straight into your own work, cultivate
research collaborations and leave inspired by new ideas.
16.25 Interactive CRISPR Roundtable Discussions
In this one hour session, you will have the opportunity to choose from four different topics and catch up on the latest
advancements and learn from your fellow colleagues in this interactive format. The topics that will be discussed are
the following:
17.25 Close of Day 1
17.30 Drinks Reception Hosted by Twist Bioscience
Ethics and impact
CRISPR/Cas-9
for human
germline editing
1. 2. 3. 4.
Correcting
mutations in human
genetic diseases
Preparing for clinical
trials involving
therapies based on
CRISPR-Cas9
Applications within
genome editing
and transcriptome
modulation
-26th
October 2016

Conference Day Two, Wednesday 26th
October 2016
7.30 Breakfast & Networking
8.30 Chairman’s Opening Remarks
Regulatory Landscape of CRISPR Across Industries
8.40 Panel Discussion: Navigating the Regulatory Environment for CRISPR as
Novel Breeding Technique
With the advent of cheaper and faster gene sequencing technology and advanced genomics,
precision gene editing provides an opportunity to add back useful characteristics by reintroducing
some of the lost diversity in a more targeted manner to accelerate the breeding process.
As the agricultural industry will be leading the way in receiving regulatory approval to produce and
market CRISPR edited crops and plants, what lessons learnt can other industries take from the
regulatory process?
The panel will discuss and answer the following questions:
• What opportunities do technologies like CRISPRs afford?
• What can be learned from the long history of safe use of random mutagenesis in the
development of useful new crop characteristics?
• How will the method of deploying new technologies like CRISPRs affect the regulatory profile in
plants and microbes?
• How might the outcomes achieved by new technologies like CRISPRs affect the regulatory
profile in plants and microbes?
• What are the industry responsibilities?
Session Chair:
Petra Jorasch,
Vice Secretary General,
German Plant
Breeders’ Association
Beat Späth,
Director Agricultural
Biotechnology,
EuropaBio
9.25 Keynote Session: Nucleic Acid Delivery Systems for RNA Therapy and
Gene Editing
• High throughput, combinatorial approaches have revolutionized small molecule drug discovery
• Here we describe our work on high throughput methods for developing and characterizing RNA
delivery and gene editing systems
• Libraries of degradable polymers and lipid-like materials have been synthesized, formulated
and screened for their ability to delivery RNA, both in vitro and in vivo
• A number of delivery formulations have been developed with in vivo efficacy, and show potential
therapeutic application for the treatment of genetic disease, viral infection, and cancer
Daniel Anderson,
Sam Goldblith
Associate Professor,
MIT
9.55 Morning Refreshments
Clinical Utility: Therapeutic Applications of CRISPR Gene Editing
10.25 Development and Optimisation of CRISPR Gene Editing for
Drug Discovery Applications
• Genome engineering is advancing at an incredible pace however applications across the types
of translational and predicative cell models now preferred for drug target discovery remains
a challenge
• What areas of the drug discovery process will genome engineering have the biggest and most
immediate impact?
• How does the pharmaceutical industry evaluate and implement a technology that is evolving so
rapidly especially as it relates to the creation of genetic disease models in iPSCs?
John Feder,
Associate Director,
Genome Biology,
-26th
October 2016

10.55 TALEN-Based Genome Editing for Adoptive T-Cell Therapies
• Harnessing talen genome editing technology for clinical applications
• Utilising talen-mediated genome editing in allogeneic T cells for adoptive immunotherapy
• CAR T cell therapies will require genome editing to reach their full potential
Laurent Poirot,
Head of Early
Discovery,
Cellectis
11.25 iTOP: A Novel Non-Viral Delivery System for Gene-Editing Based Therapeutics
• Development of the iTOP technology, a proprietary platform technology for the intracellular delivery
of bioactive molecules
• Highly efficient in vivo delivery of recombinant proteins
• In vivo application in CRISPR-Cas9 mediated gene repair
Niels Geijsen,
Founder &
Scientific Advisor,
NTrans
11.55 Bringing CRISPR Therapeutics into the Clinic
• How are CRISPR gene editing approaches distinct from the older gene therapy or nuclease methods?
• What important considerations need to be addressed as we bring CRISPR therapeutics into clinical
stage testing in patients?
• Which therapeutic areas are currently being investigated using precision gene engineering?
• What technical hurdles need resolving for successful clinical translation of CRISPR technology?
Bill Lundberg,
Chief Scientific
Officer,
CRISPR
Therapeutics
12.25 Networking Lunch
Pioneering CRISPR in Drug Discovery & Target Identification
13.25 CRISPR-Cas9 Screening with Arrayed Synthetic crRNA Libraries
• Discuss key factors for success with arrayed crRNA screening
• Discover benefits of synthetic dual CRISPR guide RNA
• Evaluate screening results using high content analysis with a cell cycle reporter line
Daniela Hüber,
Gene Modulation
Specialist,
Dharmacon,
GE Healthcare
13.55 Keynote Session: Strategies & Applications Using CRISPR and RNAi Technologies
for Identification of Novel Oncology Druggable Targets
• Genome editing approaches to accelerate drug discovery, target identification, validation & whole
genome screening
• Genome editing technology could be employed as a screening tool for identifying or validating
potential cancer genes for therapeutic development
Donald Apanovitch,
Genomics &
Biolomics,
Pfizer
14.40 Harnessing CRISPR Genome Editing for the Development of Cancer
Immunotherapies
• Highlighting protocol optimisation steps for CRISPR workflows
• Addressing how CRISPR gene editing is being used in NK cells for oncology patient screening
Evren Alici,
Assistant Professor
& Research Group
Leader,
Karolinska
Institutet
15.10 Enhancing the Takeda Cambridge Drug Discovery Toolkit with CRISPR/Cas9
• How we use CRISPR to improve efficiency and remove bottlenecks in the rodent transgenic
production pipeline
• Generating human-relevant models in vitro; our experiences using CRISPR/Cas9 to catalyse
somatic/iPS cell knockout and knockin, and the preferred strategies that we have adopted
• Looking ahead, some thoughts on how we might improve reproducibility and confidence in in vitro
genome engineered systems
Steve Sheardown,
Transgenic
Group Head,
Takeda Cambridge
15.40 Afternoon Refreshments
17.10 Chair’s Closing Remarks
17.15 Close of CRISPR & Precision Genome Editing Congress Europe 2016
Reimagine CRISPR Workflows with Precision Guides From Design to Synthesis
16.10 Interactive Workshop Hosted by Twist Bioscience
With customisation and optimisation of CRISPR design paramount, learn how to optimise CRISPR workflows to enhance the
integration of precision gene editing and down stream applications of CRISPR technology within your research.
In this interactive workshop, you will discover solutions and answers to help you:
• Overview on library design techniques for optimising CRISPR workflows
• Understand the impact of high quality DNA synthesis on enabling accurate editing
• Using specific examples of how these libraries are used in translational research to highlight the potential applications
towards development of novel molecular therapeutics
Workshop Leaders: Leigh Brody, Director Genomic Services, Desktop Genetics
Maria Celeste M. Ramirez, Director of Product Marketing, Twist Bioscience
-26th
October 2016

Partners
-26th
October 2016
Twist Bioscience
Our expertise is synthetic DNA. We have developed a manufacturing process
featuring a 10,000-well silicon platform capable of producing synthetic biology tools.
Our platform overcomes the current inefficiencies of synthetic DNA production, and
enables cost-effective, rapid and high-quality synthetic gene production. The Twist
Bioscience platform has the potential to accelerate the development of personalized
medicine, sustainable chemical production, improved agriculture production as well
as new applications such as in vivo diagnostics, biodetection and data storage.
www.twistbioscience.com
Lead Partner
Thermo Fisher Scientific Inc.
(NYSE: TMO) is the world leader
in serving science, our mission is
to enable our customers to make the world healthier, cleaner
and safer. We help our customers accelerate life Sciences
research, solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Through our
four premier brands Thermo Scientific, Life Technologies,
Fisher Scientific and Unity Lab Services we offer an unmatched
combination of innovative technologies, purchasing convenience
and comprehensive support.
www.thermoscientific.com
Programme Partner
Bio-Rad
Bio-Rad Laboratories, Inc. designs,
manufactures, and distributes a
broad range of innovative tools and services to the life science
research and clinical diagnostics markets. Founded in 1952,
Bio-Rad has a global team of more than 7,750 employees
and serves more than 100,000 research and industry
customers worldwide through the company’s global network
of operations. Throughout its existence, Bio-Rad has built
strong customer relationships that advance scientific research
and development efforts and support the introduction of new
technology used in the growing fields of genomics, proteomics,
drug discovery, food safety, and medical diagnostics.
www.bio-rad.com
Programme Partner
Dharmacon – part of GE Healthcare
Dharmacon has revolutionized the
field of RNA synthesis with the introduction of 2’-ACE synthesis
chemistry since 1995. As leaders in custom RNA synthesis,
Dharmacon was an early participant in the newly discovered
field of RNA interference, and contributed several key scientific
findings. Dharmacon RNAi products were some of the first
commercially available.
In addition, Dharmacon offers a unique set of CRISPR-Cas9
gene editing tools. The Dharmacon CRISPR-Cas9 platform
greatly simplifies the workflow of permanently knocking
out genes.
www.dharmacon.gelifesciences.com
Programme Partner
Cibus
Cibus is the leader in non-transgenic
breeding & precision gene editing in agriculture. Our mission
is to improve plants and other organisms with a new class of
non-transgenic breeding technologies. These work without
integrating foreign genetic material thus the resulting
organisms are non-transgenic. Since our improvements are
non-transgenic, they will be globally acceptable. The company
has developed & patented advanced breeding technologies
that enable precise, stable, predictable changes to be made
in plants and other organisms without integrating foreign
genetic material.
www.cibus.com
Programme Partner

Become a Partner:
Partnership Opportunities:
Contact
Diane McKenna
Commercial Director, Genomics
Tel: +44 (0)203 141 8700
Email: sponsor@hansonwade.com
As a result of the meeting
we currently are involved in
active negotiations with three
companies we met there and are
in question-answering stage with
others. Almost too much interest
for us to handle!
MD, Director,
Washington University
School of Medicine
This meeting is designed to
describe the profound impact
CRISPR is having on basic
research and therapeutic
development. It explored the
research tools, bioinformatics
and expertise needed to make
the most of this breakthrough
technology
Horizon
-26th
October 2016
Merck
Merck Millipore and Sigma-Aldrich
have come together as the life
science business of Merck KGaA, Darmstadt, Germany. With
a portfolio spanning more than 300,000 products, including a
diverse range of CRISPR reagents, whole genome screening
libraries (including Sanger arrayed and GeCKO pooled
libraries), validation services and technical expertise, our
company is committed to solving the toughest problems in life
science. For more information, visit:
www.merckmillipore.com
www.sigma-aldrich.com
Exhibitor
Ntrans
NTrans Technologies BV was
founded in 2015 based on a
proprietary platform technology for the intracellular delivery
of bioactive molecules developed at the Hubrecht Institute
of the Royal Netherlands Academy of Sciences. The iTOP
intracellular delivery technology is based on a combination
of small molecule compounds which forces the uptake of
large gulps of extracellular fluid (containing the bioactive
molecules) by the cell. Once inside, the vesicles release their
content into the cytoplasm, where the bioactive molecules can
exert their therapeutic action. Our goal is to further support
distribution and commercialization of the iTOP technology
for the research community and to develop a therapeutic
platform for iTOP based delivery of bioactive molecules. The
NTrans mission is to translate the unique iTOP technology
into revolutionary new therapies for the treatment of genetic
diseases and cancer.
www.ntranstechnologies.com
The CRISPR & Precision Genome Editing Congress is a dedicated
to enhance the very latest applications of CRISPR. This is where
VPs, Directors and C-Level Executives from Pharma, Biotech and
Academia are coming to search for the right partners.
This Congress enables the field to establish long term partnerships
to secure future success. Network with new clients and cement
existing relationships via speed networking, personal introductions
and multiple industry-wide touch points.
There is no one size fits all approach to partnership at CRISPR
Congress Europe 2016. When you work with us we will build a
partnership that helps you achieve those aims.
Several opportunities exist to educate the industry on your product
or service including speaking positions, exhibiting and hosting
receptions. Demonstrate thought leadership, showcase expertise
and educate the CRISPR community about your capabilities.
Programme Partner

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of
registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch,
refreshments and course documentation. The fee does not include travel or hotel accommodation.
Register
Full payment is due on registration. Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received more
than 14 days before the conference attendees will receive a full credit to a
future conference. Cancellations received 14 days or less (including the four-
teenth day) prior to the conference will be liable for the full fee. A substitution
from the same organization can be made at any time.
Changes to Conference & Agenda: Hanson Wade reserves the right to
postpone or cancel an event, to change the location or alter the advertised
speakers. Hanson Wade is not responsible for any loss or damage or costs
incurred as a result of substitution, alteration, postponement or cancellation
of an event for any reason and including causes beyond its control including
without limitation, acts of God, natural disasters, sabotage, accident, trade or
industrial disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by you will
be held in a database. It may be used to keep you up to date with developments
in your industry. Sometimes your details may be obtained or made available to
third parties for marketing purposes. If you do not wish your details to be used
for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6
Honduras Street, London EC1Y 0TH
Terms & Conditions
Code:6507VAT will be charged at 19%
VAT will be charged at 19%
Pricing & Venue
Venue
Pricing
I will certainly come
back to the CRISPR
Congress. I have attended
several conferences
about genome editing, but
CRISPR Congress stands
out among them.
Past Attendee
Standard Pricing
Register & Pay before
30th September 2016
Standard
Price*
Gold: Conference + 2 Workshops
23297 + VAT
(Save 4400)
23497 + VAT
(Save 4200)
Silver: Conference + 1 Workshop
22798 + VAT
(Save 4300)
22998 + VAT
(Save 4100)
Bronze: Conference Only
22299 + VAT
(Save 4200)
22499 + VAT
Workshop (Each) 2599 + VAT
Academic Pricing
Register & Pay before
30th September 2016
Standard
Price*
Gold: Conference + 2 Workshops
21917 + VAT
(Save 4300)
22017 + VAT
(Save 4200)
Silver: Conference + 1 Workshop
21658 + VAT
(Save 4200)
21758 + VAT
(Save 4100)
Bronze: Conference Only
21399 + VAT
(Save 4100)
21499 + VAT
Workshop (Each) 2359 + VAT
-26th
October 2016
Hotel Palace Berlin
Budapester, Str. 45
10787, Berlin, Germany
Accommodation:
Overnight accommodation is not
included in the registration fee
www.crispr-europe.com/register
Tel: +44 (0)20 3141 8700
Email: register@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Please note that discounts are only valid when three or more
delegates from one company book and pay at the same time.
Team discounts cannot be applied to academic pricing.
Team Discounts*

Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (7)

Similar to Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016

Similar to Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016 (20)

More from Diane McKenna

More from Diane McKenna (6)

Recently uploaded

Recently uploaded (20)

Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016